

**GOVERNMENT OF PAKISTAN**  
**THE PATENT OFFICE**  
2nd Floor, Kandawala Building,  
M.A. Jinnah Road,  
Karachi

No.2/2/2003-F.Sec.

Dated: 04-12-2007

To,

The Manager,  
Printing Corporation of Pakistan Press,  
University Road,  
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 08-9-2007 TO BE PUBLISHED ON 05-12-2007 IN  
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

ENCL:

## **NEW APPLICATIONS FOR THE PATENTS**

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1046/2007	<b><u>03-9-2007</u></b> M. D. I. Motor Development International. Luxemburg. Priority (05-09-2006 France)	“Improved compressed –Air or Gas and/or additional-energy engine having an active expansion chamber”
1047/2007	M. D. I. Motor Development International. Luxemburg	“Ambient temperature thermal energy and constant pressure cryogenic engine”
1048/2007	Novartis AG. Switzerland. Priority (04-09-2006 EP)	“Formulation of organic compounds”
1049/2007	Sanofi-Aventis. France. Priority (22-09-2006 France)	“Pyrrolizine, indolizine and quinolizine derivatives, their preparation and their therapeutic application”
1050/2007	<b><u>04-09-2007</u></b> Syngenta Participations AG. Switzerland. Priority (06-09-2006 USA)	“Pickering emulsion formulations”
1051/2007	Syngenta Participations AG. Switzerland. Priority (06-09-2006 USA)	“Pickering emulsion formulations”
1052/2007	Alfa Wassermann S.p.A. Italy. Priority (05-09-2006 Italy)	“Use of polyols to obtain stable polymorphous forms of rifaximin”
1053/2007	Glaxo Group Limited. United Kingdom. Priority (14-09-2001 GB) <b>Divisional</b>	“A phenethanolamine compound, process of its preparation and composition containing them for use in medicine”
1054/2007	Erke Erke Arastirmalari Ve Muhendislik Anonim Sirketi. Turkey. Priority (10-10-2006 Turkey)	“A motor generating and its method “
1055/2007	<b><u>05-09-2007</u></b> Pfizer Products Inc. USA. Priority (08-09-2006 USA)	“Diaryl ether derivatives and uses thereof”

1056/2007	Lanxess Inc. Canada. Priority (08-09-2007 USA)	“Method to produce silica reinforced elastomer compounds with improved scorch safety”
1057/2007	Sanofi-Aventis. France. Priority (22-09-2006 France)	“2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof”
1058/2007	<b><u>06-09-2007</u></b> Novartis AG. Switzerland. Priority (08-09-2006 EP)	“Biaryl sulfonamide derivatives”
1059/2007	<b><u>07-09-2007</u></b> Shahid Kamal Khan Karachi-Pakistan	“Plastic and metal tamper proof protective cover for pipe union joints”
1060/2007	Wyeth. USA. Priority (08-09-2006 USA)	“Arginine wash in protein purification using affinity chromatography”
1061/2007	Wyeth. USA. Priority (08-09-2006 USA)	“Dry powder compound formulations and uses thereof”
1062/2007	Al-Dhefaf for Tobacco & Molasses Industries Co. P.S.C. Amman.	“Tobacco cartridge particularly for use with narghiles”
1063/2007	1BP Exploration Operating Company Limited. England 2. BP Corporation North America Inc. USA Priority (08-09-2006 USA)	“Hydrocarbon recovery process”
1064/2007	<b><u>08-09-2007</u></b> Methanol Casale S.A. Switzerland. Priority (11-09-2006 EP)	“Isothermal reactor”
1065/2007	Takeda Pharmaceutical Company Limited. Japan. Priority (13-09-2006 USA)	“Administration of dipeptidyl peptidase inhibitors”

## APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


218/99      British Biotech  
Pharmaceuticals Limited,  
United Kingdom

“N-formyl hydroxylamine”

(A61K, 31/16)

139303

Compound of formula (I) are antibacterials;



Wherein

r1 represents hydrogen, or C<sub>r</sub>-C<sub>6</sub> alkyl or C<sub>r</sub>-C<sub>6</sub> alkyl substituted by one or more halogen atoms; R<sub>2</sub> represents a group R<sub>10</sub>-(X)<sub>n</sub>-(ALK)<sub>m</sub> wherein R<sub>10</sub> represents hydrogen, or a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>) alkoxy, hydroxy, mercapto, (C<sub>1</sub>-C<sub>6</sub>)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, -COOH, -CONH<sub>2</sub>, -COOR<sup>A</sup>, -NHCOR<sup>A</sup>, CONHR<sup>A</sup>, -NHR<sup>A</sup>, -NR<sup>A</sup>R<sup>B</sup>, or -CONR<sup>A</sup> R<sup>B</sup> wherein R<sup>A</sup> and R<sup>B</sup> are independently a (C<sub>r</sub>-C<sub>6</sub>)alkyl group, and ALK represents a straight or branched divalent G<sub>1</sub>-C<sub>6</sub> alkylene, C<sub>2</sub>-C<sub>6</sub> atkenylene, or C<sub>2</sub>-C<sub>6</sub> alkynylene radical, and may be interrupted by one or more non-adjacent -NH-, -O- or -S- linkages, X represents -NH-, -O- Or -S-, and m and n are independently 0 or 1; and A represents a group as defined in the specification.

869/2002 Warner-Lambert  
Company,  
USA

“ New anhydrous crystalline form of gabapentin”

(CO7C 10/14)

139304

Described are new crystalline anhydrous form of gabapentin formed from gabapentin monohydrate.

797/2003 Pharmacia Italia S.p.A.  
Italy

The new crystalline form provide advantages in the manufacture of the therapeutic agent.

“Composition comprising an indolinone compound”

(A61K, 31/404 )

139305

The present invention feature composition of indolinone. The composition is suitable for parenteral or oral administration, wherein the composition comprises an indolinone and a pharmaceutically acceptable carrier therefore. The composition and the compound themselves are useful for the treatment of protein kinase related disorders.